Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31198
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarretero Gomez, Juana-
dc.contributor.authorArévalo-Lorido, José Carlos-
dc.contributor.authorGómez Huelgas, Ricardo-
dc.contributor.authorGarcía de Lucas, Dolores-
dc.contributor.authorMateos Polo, Lourdes-
dc.contributor.authorVarela Aguilar, Jose M.-
dc.contributor.authorSeguí-Ripoll, José Miguel-
dc.contributor.authorEna, Javier-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-07T10:05:31Z-
dc.date.available2024-02-07T10:05:31Z-
dc.date.created2018-09-04-
dc.identifier.citationCanadian Journal of Diabetes. 43(2019) 186-192es_ES
dc.identifier.issn2352-3840-
dc.identifier.issn1499-2671-
dc.identifier.urihttps://hdl.handle.net/11000/31198-
dc.description.abstractObjectives: Scientific literature about the combination of glucagon-like peptide-1 receptor agonists (GLP1ra) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in older patients is scarce. We sought to assess the real-world efficacy and safety of SGLT2 inhibitors and GLP-1ra combination therapy in older patients (>65 years of age). Methods: This was an observational, prospective, multicenter study based on clinical practice. Patients were stratified according to tertiles of baseline glycated hemoglobin (A1C) levels and to treatment schedule. Results: We included 113 patients (65.5% men, mean age 70.4±8.8 years). The body mass index was 36.5 (±6.6) kg/m2. The baseline A1C level was 8.0% (±1.2%). At the 6-month follow up, we found a significant reduction in A1C levels (–1.1%; p<0.0001), body mass index (–2.1 kg/m2; p<0.00003) and systolic blood pressure (–13 mmHg; p<0.000005). Patients who had the highest baseline A1C levels (≥8.4%) showed greater improvement in A1C levels (p<0.0001), weight (p<0.0001) and quality-of-life scores (p<0.0001). The greatest reduction in A1C levels and weight was seen in patients who started both drugs simultaneously (p<0.0001). The second greatest reduction was seen when GLP-1ra was added to previous treatment with an SGLT2i (p<0.0001). Also of note was a decrease in systolic blood pressure in patients for whom an SGLT2i was added to previous GLP-1ra treatment (p<0.0001). Of the patients, 34.3% achieved the combined endpoint of A1C levels <7% and weight loss ≥5% without hypoglycemia. Conclusions: This study’s findings provide evidence of clinically meaningful reductions in A1C level, body weight and systolic blood pressure in older patients with type 2 diabetes who are taking combined regimens. The dropout and hypoglycemia rates were minimal, and treatment was tolerated well.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent7es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectbody weightes_ES
dc.subjectglycemic controles_ES
dc.subjectglucagon-like peptide-1 receptor agonists (GLP-1ra)es_ES
dc.subjectolder patientes_ES
dc.subjectsodium-glucose cotransporter 2 inhibitors (SGLT2i)es_ES
dc.titleCombination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jcjd.2018.09.001es_ES
Appears in Collections:
Artículos Medicina Clínica


no-thumbnailView/Open:

 Combination TherapyWith Glucagon-Like Peptide-1 Receptor.pdf



735,99 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???